Brief: Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders
25/09/2024 13:41
Sept 25 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO AND OPKO HEALTH PROVIDE UPDATE ON PK/PD RESULTS
OF
ORAL OXYNTOMODULIN (GLP-1/GLUCAGON) PEPTIDE TABLET CANDIDATE FOR
OBESITY AND METABOLIC DISORDERS
* ENTERA BIO LTD - ORAL OXM REDUCED PLASMA GLUCOSE LEVELS
SIGNIFICANTLY
Source text for Eikon: ID:nGNX5r8csW
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement